| Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review M Sałaga, H Zatorski, M Sobczak, C Chen, J Fichna Current treatment options in oncology 15, 405-420, 2014 | 118 | 2014 |
| Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases M Sobczak, A Fabisiak, N Murawska, E Wesołowska, P Wierzbicka, ... Pharmacological Reports 66 (5), 766-775, 2014 | 115 | 2014 |
| Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations A Párniczky, T Lantos, EM Tóth, Z Szakács, S Gódi, R Hágendorn, D Illés, ... Pancreatology 19 (4), 488-499, 2019 | 109 | 2019 |
| Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH) M Sałaga, A Mokrowiecka, PK Zakrzewski, A Cygankiewicz, E Leishman, ... Journal of Crohn's and Colitis 8 (9), 998-1009, 2014 | 106 | 2014 |
| Experimental colitis in mice is attenuated by topical administration of chlorogenic acid H Zatorski, M Sałaga, M Zielińska, A Piechota-Polańczyk, K Owczarek, ... Naunyn-schmiedeberg's Archives of Pharmacology 388, 643-651, 2015 | 83 | 2015 |
| Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid‐like fatty acid amides J Fichna, M Sałaga, J Stuart, D Saur, M Sobczak, H Zatorski, ... Neurogastroenterology & Motility 26 (4), 470-481, 2014 | 59 | 2014 |
| Synthesis and evaluation of anti‐inflammatory properties of silver nanoparticle suspensions in experimental colitis in mice K Siczek, H Zatorski, A Chmielowiec‐Korzeniowska, J Pulit‐Prociak, ... Chemical Biology & Drug Design 89 (4), 538-547, 2017 | 48 | 2017 |
| Role of environmental pollution in irritable bowel syndrome M Marynowski, A Likońska, H Zatorski, J Fichna World Journal of Gastroenterology: WJG 21 (40), 11371, 2015 | 47 | 2015 |
| Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner A Drzazga, H Kristinsson, M Sałaga, H Zatorski, M Koziołkiewicz, ... Molecular and cellular endocrinology 472, 117-125, 2018 | 36 | 2018 |
| Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge and future perspectives H Zatorski, M Sałaga, J Fichna Naunyn-Schmiedeberg's archives of pharmacology 392, 1321-1330, 2019 | 35 | 2019 |
| Evaluation of anti-inflammatory effect of silver-coated glass beads in mice with experimentally induced colitis as a new type of treatment in inflammatory bowel disease K Siczek, H Zatorski, A Chmielowiec-Korzeniowska, R Kordek, ... Pharmacological Reports 69, 386-392, 2017 | 31 | 2017 |
| Dietary interventions in inflammatory bowel disease M Godala, E Gaszyńska, H Zatorski, E Małecka-Wojciesko Nutrients 14 (20), 4261, 2022 | 28 | 2022 |
| Pathophysiology and risk factors in peptic ulcer disease H Zatorski Introduction to Gastrointestinal Diseases Vol. 2, 7-20, 2017 | 27 | 2017 |
| Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment P Dudek, A Fabisiak, H Zatorski, E Malecka-Wojciesko, ... Journal of Clinical Medicine 10 (23), 5660, 2021 | 25 | 2021 |
| AdipoRon, an orally active, synthetic agonist of AdipoR1 and AdipoR2 receptors has gastroprotective effect in experimentally induced gastric ulcers in mice H Zatorski, M Salaga, M Zielińska, K Majchrzak, A Binienda, R Kordek, ... Molecules 26 (10), 2946, 2021 | 21 | 2021 |
| Relamorelin and other ghrelin receptor agonists-future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease H Zatorski, P Mosinska, M Storr, J Fichna J Physiol Pharmacol 68 (6), 797-805, 2017 | 21 | 2017 |
| Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice M Salaga, H Zatorski, M Zielińska, P Mosinska, JP Timmermans, ... Naunyn-Schmiedeberg's Archives of Pharmacology 390, 1015-1027, 2017 | 20 | 2017 |
| Future treatment of constipation-associated disorders: role of relamorelin and other ghrelin receptor agonists P Mosińska, H Zatorski, M Storr, J Fichna Journal of Neurogastroenterology and Motility 23 (2), 171, 2017 | 20 | 2017 |
| Acid suppression therapy, gastrointestinal bleeding and infection in acute pancreatitis–An international cohort study A Demcsák, A Soós, L Kincses, I Capunge, G Minkov, ... Pancreatology 20 (7), 1323-1331, 2020 | 19 | 2020 |
| Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy H Zatorski, M Marynowski, J Fichna Pharmacological Reports 68, 809-815, 2016 | 18 | 2016 |
Jakub FichnaMedical University of Lodz, Poland在 umed.lodz.pl 的电子邮件经过验证
Jakub FichnaMedical University of Lodz, Poland在 umed.lodz.pl 的电子邮件经过验证